471 related articles for article (PubMed ID: 23530718)
1. Pertuzumab : evolving therapeutic strategies in the management of HER2-overexpressing breast cancer.
O'Sullivan CC; Swain SM
Expert Opin Biol Ther; 2013 May; 13(5):779-90. PubMed ID: 23530718
[TBL] [Abstract][Full Text] [Related]
2. Pertuzumab for the treatment of human epidermal growth factor receptor type 2-positive metastatic breast cancer.
Chung C; Lam MS
Am J Health Syst Pharm; 2013 Sep; 70(18):1579-87. PubMed ID: 23988598
[TBL] [Abstract][Full Text] [Related]
3. [Pertuzumab (Perjeta®) approval in HER2-positive metastatic breast cancers].
Sabatier R; Gonçalves A
Bull Cancer; 2014; 101(7-8):765-71. PubMed ID: 25091659
[TBL] [Abstract][Full Text] [Related]
4. Pertuzumab: development beyond breast cancer.
Barthélémy P; Leblanc J; Goldbarg V; Wendling F; Kurtz JE
Anticancer Res; 2014 Apr; 34(4):1483-91. PubMed ID: 24692675
[TBL] [Abstract][Full Text] [Related]
5. Use of pertuzumab for the treatment of HER2-positive metastatic breast cancer.
De Mattos-Arruda L; Cortes J
Adv Ther; 2013 Jul; 30(7):645-58. PubMed ID: 23881722
[TBL] [Abstract][Full Text] [Related]
6. Pertuzumab in HER2-positive breast cancer.
Sendur MA; Aksoy S; Altundag K
Curr Med Res Opin; 2012 Oct; 28(10):1709-16. PubMed ID: 22953713
[TBL] [Abstract][Full Text] [Related]
7. Pertuzumab and its accelerated approval: evolving treatment paradigms and new challenges in the management of HER2-positive breast cancer.
O'Sullivan CC; Connolly RM
Oncology (Williston Park); 2014 Mar; 28(3):186-94, 196. PubMed ID: 24855725
[TBL] [Abstract][Full Text] [Related]
8. Pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Kawajiri H; Takashima T; Kashiwagi S; Noda S; Onoda N; Hirakawa K
Expert Rev Anticancer Ther; 2015 Jan; 15(1):17-26. PubMed ID: 25494663
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics, pharmacodynamics and clinical efficacy of pertuzumab in breast cancer therapy.
Rocca A; Andreis D; Fedeli A; Maltoni R; Sarti S; Cecconetto L; Pietri E; Schirone A; Bravaccini S; Serra P; Farolfi A; Amadori D
Expert Opin Drug Metab Toxicol; 2015; 11(10):1647-63. PubMed ID: 26307328
[TBL] [Abstract][Full Text] [Related]
10. Pertuzumab for the treatment of breast cancer: a safety review.
Gao J; Swain SM
Expert Opin Drug Saf; 2016 Jun; 15(6):853-63. PubMed ID: 26982349
[TBL] [Abstract][Full Text] [Related]
11. Pertuzumab: a new targeted therapy for HER2-positive metastatic breast cancer.
Malenfant SJ; Eckmann KR; Barnett CM
Pharmacotherapy; 2014 Jan; 34(1):60-71. PubMed ID: 23918291
[TBL] [Abstract][Full Text] [Related]
12. Pertuzumab and breast cancer: another piece in the anti-HER2 puzzle.
Gerratana L; Bonotto M; Bozza C; Ongaro E; Fanotto V; Pelizzari G; Puglisi F
Expert Opin Biol Ther; 2017 Mar; 17(3):365-374. PubMed ID: 28092723
[TBL] [Abstract][Full Text] [Related]
13. CLEOPATRA: a phase III evaluation of pertuzumab and trastuzumab for HER2-positive metastatic breast cancer.
Baselga J; Swain SM
Clin Breast Cancer; 2010 Dec; 10(6):489-91. PubMed ID: 21147694
[TBL] [Abstract][Full Text] [Related]
14. First FDA approval of dual anti-HER2 regimen: pertuzumab in combination with trastuzumab and docetaxel for HER2-positive metastatic breast cancer.
Blumenthal GM; Scher NS; Cortazar P; Chattopadhyay S; Tang S; Song P; Liu Q; Ringgold K; Pilaro AM; Tilley A; King KE; Graham L; Rellahan BL; Weinberg WC; Chi B; Thomas C; Hughes P; Ibrahim A; Justice R; Pazdur R
Clin Cancer Res; 2013 Sep; 19(18):4911-6. PubMed ID: 23801166
[TBL] [Abstract][Full Text] [Related]
15. Pertuzumab: optimizing HER2 blockade.
Metzger-Filho O; Winer EP; Krop I
Clin Cancer Res; 2013 Oct; 19(20):5552-6. PubMed ID: 23942091
[TBL] [Abstract][Full Text] [Related]
16. Pertuzumab: a review of its use for first-line combination treatment of HER2-positive metastatic breast cancer.
McCormack PL
Drugs; 2013 Sep; 73(13):1491-502. PubMed ID: 23982598
[TBL] [Abstract][Full Text] [Related]
17. Pertuzumab: a new anti-HER2 drug in the management of women with breast cancer.
Dawood S; Sirohi B
Future Oncol; 2015; 11(6):923-31. PubMed ID: 25760974
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab for patients with HER2 positive breast cancer: delivery, duration and combination therapies.
Pinto AC; Ades F; de Azambuja E; Piccart-Gebhart M
Breast; 2013 Aug; 22 Suppl 2():S152-5. PubMed ID: 24074778
[TBL] [Abstract][Full Text] [Related]
19. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial.
Gianni L; Pienkowski T; Im YH; Roman L; Tseng LM; Liu MC; Lluch A; Staroslawska E; de la Haba-Rodriguez J; Im SA; Pedrini JL; Poirier B; Morandi P; Semiglazov V; Srimuninnimit V; Bianchi G; Szado T; Ratnayake J; Ross G; Valagussa P
Lancet Oncol; 2012 Jan; 13(1):25-32. PubMed ID: 22153890
[TBL] [Abstract][Full Text] [Related]
20. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
